The settlement resolves allegations that between March 1, 2020, and September 30, 2022, Biohaven paid kickbacks to providers to present at speaker programs designed to promote Nurtec to Medicaid and ...

Biohaven Ltd. (NYSE:BHVN – Get Free Report) was the target of a large decline in short interest in January. As of January 31st, there was short interest totalling 9,440,000 shares, a decline of ...

Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant) are brand-name oral tablets. They’re both prescribed for treating migraine in adults. This article explains the main similarities and differences ...

Shares of Biohaven Ltd. (NYSE:BHVN – Get Free Report) have received an average rating of “Buy” from the fifteen brokerages that are covering the company, MarketBeat Ratings reports.

Biohaven's neuroinnovation portfolio includes FDA-approved NURTEC ODT (rimegepant) for the acute treatment of migraine and a broad pipeline of late-stage product candidates across three distinct ...

Before market open, Biohaven announced that the U.S. Food and Drug Administration (FDA) had accepted its New Drug Application (NDA) for troriluzole. This is a once-daily oral treatment for adults ...